Prognostic value of inflammation-based markers in limited disease small-cell lung cancer (LD-SCLC)

被引：0
|
作者：
Kaesmann, L. [1 ]
Bolm, L. [1 ]
Janssen, S. [1 ]
Rades, D. [1 ]
机构：
[1] Univ Lubeck, Dept Radiat Oncol, Lubeck, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2017年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V18-3-jD
引用
收藏
页码：S53 / S54
页数：2
相关论文
共 50 条
  • [11] Phase I study of amrubicin and cisplatin with concurrent thoracic radiotherapy (TRT) in limited-disease small cell lung cancer (LD-SCLC)
    Shimada, Midori
    Nakatomi, Katsumi
    Yamaguchi, Hiroyuki
    Dotsu, Yosuke
    Ikeda, Takaya
    Sugasaki, Nanae
    Yamazaki, Takuya
    Hayashi, Nobuyuki
    Nakamura, Yoichi
    Fukuda, Minoru
    Mukae, Hiroshi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [12] Phase I Study of Amrubicin and Cisplatin with Concurrent Thoracic Radiotherapy (TRT) in Limited-Disease Small Cell Lung Cancer (LD-SCLC)
    Fukuda, M.
    Shimada, M.
    Yamaguchi, H.
    Kitazaki, T.
    Ogawara, D.
    Nakatomi, K.
    Nakamura, Y.
    Yamazaki, T.
    Hayashi, N.
    Mukae, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S814 - S815
  • [13] A systemic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancer
    Zhou, Ting
    Hong, Shaodong
    Hu, Zhihuang
    Hou, Xue
    Huang, Yan
    Zhao, Hongyun
    Liang, Wenhua
    Zhao, Yuanyuan
    Fang, Wenfeng
    Wu, Xuan
    Qin, Tao
    Zhang, Li
    TUMOR BIOLOGY, 2015, 36 (01) : 337 - 343
  • [14] PROGNOSTIC VALUE OF PLASMA CARCINOEMBRYONIC (CEA) DETERMINATIONS IN SMALL-CELL LUNG-CANCER (SCLC)
    MALKIN, A
    MALKIN, DG
    EVANS, WK
    FELD, R
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 185 - 185
  • [15] Prognostic value of carbohydrate tumor markers and inflammation-based markers in gastric cancer
    Kong, W.
    Wang, Q.
    Wei, J.
    Yang, Y.
    Zhang, Y.
    Zou, Z.
    Liu, B.
    ANNALS OF ONCOLOGY, 2015, 26
  • [16] Reduction in tumor size after the first course of cisplatin/etoposide (PE) in limited disease small-cell lung cancer (LD SCLC).
    Gronberg, Bjorn Henning
    Levin, Nina
    Sundstrom, Stein
    Flotten, Oystein
    Brustugun, Odd Terje
    Brunsvig, Paal
    Bremnes, Roy M.
    Kaasa, Stein
    Halvorsen, Tarje Onsoien
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [17] High-dose ifosfamide, carboplatin and etoposide (HD-ICE) with peripheral blood stem cell transfusion (PBSCT) for limited stage small-cell lung cancer (LD-SCLC).
    Katakami, N.
    Nishimura, T.
    Higashi, Y.
    Seo, R.
    Kubota, M.
    Naya, R.
    Hayashi, M.
    Ikeda, A.
    Tomii, K.
    Ishihara, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 386S - 386S
  • [18] THE COMBINED USE OF LDH AND CEA AS INDEPENDENT PROGNOSTIC MARKERS FOR SMALL-CELL LUNG-CANCER (SCLC)
    WANG, T
    FELD, R
    SAGMAN, U
    EVANS, WK
    SHEPHERD, FA
    WARR, D
    DEBOER, G
    CIAMPI, A
    MALKIN, DG
    MALKIN, A
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 162 - 162
  • [19] Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer
    Martin, H. L.
    Ohara, K.
    Kiberu, A.
    Van Hagen, T.
    Davidson, A.
    Khattak, M. A.
    INTERNAL MEDICINE JOURNAL, 2014, 44 (07) : 676 - 682
  • [20] SMOOTHED HAZARD PLOTS IN LIMITED DISEASE (LD) SMALL-CELL LUNG-CANCER (SCLC) EXPLORATORY ANALYSIS OF KARNOFSKY STATUS ON RISK OF DEATH
    EVANS, L
    SCHER, H
    GELLER, N
    TRUST, A
    YAGODA, A
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 186 - 186
12345